Industry & Policy News

[CNN] The US FDA has issued a new warning about the possible risk of secondary cancers in cancer patients who have been treated with a form of immunotherapy called chimeric antigen receptor T-cell, or CAR-T cell, therapy.

[Bristol Myers Squibb] Bristol Myers Squibb announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended marketing authorization approval of Abecma® for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies.

[Mount Sinai] The Icahn School of Medicine at Mount Sinai has been awarded a grant of more than $4 million from The Leona M. and Harry B. Helmsley Charitable Trust to support an innovative research project aimed at understanding the early stages of Crohn’s disease before noticeable symptoms develop.

[NUS Mechanobiology Institute] The Mechanobiology Institute at the National University of Singapore (NUS) has recently secured S$49 million in funding from the National Research Foundation to promote research aimed at advancing the field of mechanobiology and turning scientific breakthroughs into action by developing novel technologies and therapeutic targets for the treatment of age-related ailments.

Ocular Therapeutix, Inc. announced that the US FDA has agreed to a SPA Agreement Modification for the Company’s pivotal Phase III SOL clinical trial of AXPAXLI™ for the treatment of wet...

[Nature] After decades of frustration and failed attempts, scientists might finally be on the cusp of developing therapies to restore immune ‘tolerance’ in conditions such as diabetes, lupus and multiple sclerosis.